Yuyu Pharma, Inc.

Symbol: 000220.KS

KSC

5400

KRW

company-market-status

-23.0591
P/E ratio
0.1778
PEG ratio
88.29B
Mrk Cap
0.02%
Div Yield

Yuyu Pharma, Inc. (000220-KS) Stock Split, History Data

Оборотен капитал

Всички числа в милиони

	2022	2021	2020	2019	2018	2017
Парични средства и инвестиции	25838.58	50263.47	20322.82	26846.23	26966.55	19812.44
Приемници	0.00	0.00	0.00	0.00	0.00	0.00
Инвентарна книга	39832.04	25225.28	23688.89	17015.98	15615.96	19593.38
Други	439.30	493.98	426.45	114.22	225.19	0.00
Общо текущи активи	96357.75	98887.92	64466.55	65053.89	68869.66	63470.37
Acc Payable	15840.53	8982.26	5286.76	6385.09	5056.81	8453.25
Краткосрочен дълг	37424.96	10427.31	4978.16	23872.47	12366.20	18070.00
Други текущи пасиви	11050.04	10605.17	8133.78	12238.07	10364.56	8960.39
Текущи пасиви	64315.53	30014.75	18398.70	42495.63	27787.57	35483.64

Капиталова структура

Всички числа в милиони

Общо активи

196576,56 щ.д.

Общо активи

196576561000,00 щ.д.

Общо задължения

75838,64 щ.д.

Общо задължения

75838637000,00 щ.д.

Дългосрочен дълг

2402,39 щ.д.

Дългосрочен дълг

2402389000,00 щ.д.

Парични средства и екви

24675,92 щ.д.

Парични средства и екви

24675923410,00 щ.д.

Goodwill

50,83 щ.д.

Goodwill

50829000,00 щ.д.

Неразпределена печалба

29199,26 щ.д.

Неразпределена печалба

29199259860,00 щ.д.

Обикновени акции

6208,29 щ.д.

Обикновени акции

6208290000,00 щ.д.

Стойност на предприятието

0,00 щ.д.

Дивиденти за маса

Подзаглавие на таблицата Dividends

Години	Q1	Q4	Общо
2000	10.123	0.000	10.123
2001	33.962	0.000	33.962
2002	80.000	0.000	80.000
2003	90.000	0.000	90.000
2004	100.000	0.000	100.000
2005	105.000	0.000	105.000
2006	110.000	0.000	110.000
2007	120.000	0.000	120.000
2008	150.000	0.000	150.000
2009	35.000	0.000	35.000
2010	33.840	0.000	33.840
2011	50.000	0.000	50.000
2012	60.000	0.000	60.000
2013	80.000	0.000	80.000
2014	90.000	0.000	90.000
2015	90.000	0.000	90.000
2016	90.000	0.000	90.000
2017	90.000	95.000	185.000
2018	0.000	100.000	100.000
2019	0.000	105.000	105.000
2020	0.000	105.000	105.000
2021	0.000	105.000	105.000
2022	0.000	105.000	105.000

Печалба на акция

Подзаглавие "Доходи на акция

Години	Q1	Q4	Общо
2000	10.123	0.000	10.123
2001	33.962	0.000	33.962
2002	80.000	0.000	80.000
2003	90.000	0.000	90.000
2004	100.000	0.000	100.000
2005	105.000	0.000	105.000
2006	110.000	0.000	110.000
2007	120.000	0.000	120.000
2008	150.000	0.000	150.000
2009	35.000	0.000	35.000
2010	33.840	0.000	33.840
2011	50.000	0.000	50.000
2012	60.000	0.000	60.000
2013	80.000	0.000	80.000
2014	90.000	0.000	90.000
2015	90.000	0.000	90.000
2016	90.000	0.000	90.000
2017	90.000	95.000	185.000
2018	0.000	100.000	100.000
2019	0.000	105.000	105.000
2020	0.000	105.000	105.000
2021	0.000	105.000	105.000
2022	0.000	105.000	105.000

Подобни запаси

Може да се интересувате и от

CHSYF

China Medical System Holdings Limited.

1.381 USD

PNK

DHT-UN.TO

DRI Healthcare Trust.

10.22 CAD

TSX

RMTI

Rockwell Medical, Inc..

4.55 USD

NASDAQ

BOD.AX

Bod Science Limited.

0.047 AUD

ASX

AVCN.TO

Avicanna Inc..

0.31 CAD

TSX

600664.SS

Harbin Pharmaceutical Group Co., Ltd..

3.53 CNY

SHH

PDPL.NS

Parenteral Drugs (India) Limited.

4 INR

NSE

SCYX

SCYNEXIS, Inc..

2.76 USD

NASDAQ

001360.KS

SAMSUNG PHARM. Co., LTD..

3240 KRW

KSC

Frequently Asked Question

Why is your stock tool better than competitors?

Numfin provides most features for free and gives you accurate and expert data about public companies. We also offer unique features like AI copilot that are not found on other platforms

Can I trust the data on your website and where do they come from?

Absolutely. We receive the data from our partners and other official sources, such as popular stock exchanges (NASDAQ, NYSE, and others), SEC.gov, and other official platforms. Our data provider, FinancialModeling, also provides information for portals like Moody's, Harvard, Chevron, and others. All this proves the accuracy and authority of the information.

Who creates the content on your website and is it approved by experts in finance and investing?

All financial data is received from our data provider and then verified by industry experts. Additionally, we use various AI tools like ChatGPT to present content in a user-friendly and well-structured manner.

What problem does your tool solve? Who is the target audience for your tool

Our main goal is to present accurate and expert information about public companies in a structured manner. We work with investors and financial professionals who have a long-term outlook. Our community consists of private investors, business owners, stock analysts, fund managers, and people who are interested in investing.

Why did you decide to create your tool?

While managing our own money, we searched for the best analytical tool to help us better analyze public companies. Most websites that provided analytics for professional investors were expensive, and the cheap tools were either limited in functionality or lacked valuable company data. Even worse, some of them presented incorrect numbers. As a result, we combined our experience in business, IT, and finance to create the most affordable and useful solution for investors and anyone interested in finance and stock analysis.

What is the difference between free and paid options? Should I buy Pro version from start or it's ok to have a free version?

Most features on our website are free so that many people can use it to analyze companies on the world's top stock exchanges. However, some features, such as our artificial intelligence chat, advanced analytics, filters, and storing of vast historical data, require additional servers from our end. Therefore, we rely on your support to keep this amazing project running. If you would like to experience the full potential of our service, we strongly recommend that you purchase the PRO version, which comes with a 30-day money-back guarantee

Who is your team and do they have enough experience?

You can read about our team here, or you can contact us at [email protected] for more information.